Close

Roth Capital Lifts PT on Ligand (LGND) to $92; Still Sees Plenty of Positive Catalysts Ahead

February 12, 2014 7:23 AM EST Send to a Friend
Roth Capital reaffirms Ligand Pharmaceuticals (Nasdaq: LGND) at Buy, but lifts its price target from $69 up to $92.

This article: 209 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login